XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.
Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.
XOMA Royalty Corporation (NASDAQ: XOMA), aggregatore di royalty nel settore biotecnologico, ha comunicato la sua partecipazione alla 27ª Conferenza Annuale Globale sugli Investimenti organizzata da H.C. Wainwright. Il team dirigenziale, con CEO Owen Hughes e CIO Brad Sitko, terrà un aggiornamento aziendale lunedì 8 settembre 2025 alle 9:00 ET.
Gli investitori potranno seguire la presentazione tramite webcast o attraverso la sezione Investor Relations del sito di XOMA all'indirizzo www.xoma.com.
XOMA Royalty Corporation (NASDAQ: XOMA), un agregador de regalías biotecnológicas, ha anunciado su participación en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright. El equipo directivo, incluido el CEO Owen Hughes y el CIO Brad Sitko, ofrecerá una actualización de la compañía el lunes 8 de septiembre de 2025 a las 9:00 ET.
Los inversores podrán acceder a la presentación mediante un webcast o a través de la sección de relaciones con inversores en el sitio web de XOMA: www.xoma.com.
XOMA Royalty Corporation (NASDAQ: XOMA), 바이오테크 로열티 집적업체가 H.C. Wainwright의 제27회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. CEO Owen Hughes와 CIO Brad Sitko를 포함한 경영진이 2025년 9월 8일 월요일 동부시간(ET) 오전 9시에 회사 현황 발표를 진행합니다.
투자자는 웹캐스트 링크나 XOMA 웹사이트의 투자자 관계(Investor Relations) 페이지(www.xoma.com)를 통해 발표를 시청할 수 있습니다.
XOMA Royalty Corporation (NASDAQ: XOMA), un agrégateur de redevances biotechnologiques, a annoncé sa participation à la 27e Conférence annuelle mondiale sur l'investissement organisée par H.C. Wainwright. L'équipe dirigeante, comprenant le CEO Owen Hughes et le CIO Brad Sitko, présentera une mise à jour de la société le lundi 8 septembre 2025 à 9h00 ET.
Les investisseurs pourront suivre la présentation via un webcast ou depuis la rubrique Relations investisseurs du site de XOMA à l'adresse www.xoma.com.
XOMA Royalty Corporation (NASDAQ: XOMA), ein Biotech-Royalty-Aggregator, hat seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference angekündigt. Das Führungsteam, darunter CEO Owen Hughes und CIO Brad Sitko, wird ein Unternehmensupdate präsentieren am Montag, den 8. September 2025 um 9:00 Uhr ET.
Investoren können die Präsentation per Webcast verfolgen oder über den Investor-Relations-Bereich auf XOMAs Website unter www.xoma.com abrufen.
- None.
- None.
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.
Mr. Hughes and Mr. Sitko will present on Monday, September 8, 2025 at 9:00 AM ET. The webcast for the presentation can be accessed by visiting https://bit.ly/4mjFgkY. XOMA Royalty’s presentation can be also accessed by visiting the investor relations section of the Company’s website at www.xoma.com.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| XOMA Investor Contact | XOMA Media Contact |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty | KV Consulting & Management |
| +1 646-438-9754 | kathy@kathyvincent.com |
| juliane.snowden@xoma.com |
FAQ
When is XOMA Royalty (NASDAQ: XOMA) presenting at the H.C. Wainwright Conference?
Who will be presenting at the H.C. Wainwright Conference for XOMA Royalty?
How can investors access XOMA Royalty's H.C. Wainwright Conference presentation?
What type of company is XOMA Royalty (NASDAQ: XOMA)?
